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Abstract
Background: Fractures of the proximal humerus are associated with a profound temporary and sometimes
permanent, impairment of function and quality of life. The treatment of comminuted fractures of the proximal
humerus like selected three-or four-part fractures and split fractures of the humeral head is a demanding and
unresolved problem, especially in the elderly. Locking plates appear to offer improved fixation; however, screw cut-
out rates ranges due to fracture collapse are high. As this may lead to higher rates of revision surgery, it may be
preferable to treat comminuted fractures in the elderly primarily with a prosthesis or non-operatively. Results from
case series and a small-sample randomized controlled trial (RCT) suggest improved function and less pain after
primary hemiarthroplasty (HA); however these studies had some limitations and a RCT is needed. The primary aim
of this study is to compare the Constant scores (reflecting functional outcome and pain) at one year after primary
HA versus non-operative treatment in elderly patients who sustained a comminuted proximal humeral fracture.
Secondary aims include effects on functional outcome, pain, complications, quality of life, and cost-effectiveness.
Methods/Design: A prospective, multi-center RCT will be conducted in nine centers in the Netherlands and
Belgium. Eighty patients over 65 years of age, who have sustained a three-or four part, or split head proximal
humeral fracture will be randomized between primary hemiarthroplasty and conservative treatment. The primary
outcome is the Constant score, which indicates pain and function. Secondary outcomes include the Disability of
the Arm and Shoulder (DASH) score, Visual Analogue Scale (VAS) for pain, radiographic healing, health-related
quality of life (Short-form-36, EuroQol-5D) and healthcare consumption. Cost-effectiveness ratios will be determined
for both trial arms. Outcome will be monitored at regular intervals over the subsequent 24 months (1, 3 and 6
weeks, and 3, 6, 12, 18, and 24 months). Data will be analyzed on an intention to treat basis, using univariate and
multivariable analyses.
Discussion: This trial will provide level-1 evidence on the effectiveness of the two mostly applied treatment
options for three-or four part and split head proximal humeral fractures in the elderly. These data may support the
development of a clinical guideline for treatment of these traumatic injuries.
Trial registration: Netherlands Trial Register (NTR): NTR2040.
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Fractures of the proximal humerus are one of the most
frequently encountered fractures in the elderly. The
incidence is approximately 66 per 10,000 person years
[1]. Most of these fractures are treated non-operatively
and careful early motion with varying results. Especially,
the treatment of three-or four-part fractures and split
head humeral fractures is an unresolved problem [1-4].
Locking plates have been used during the last decade.
They appear to offer improved fixation, however at con-
siderable rates of complications such as non-union, mal-
union, or complaints of hardware (e.g., impingement).
Also, the prevalence of screw cut-out ranges from 11 to
43% due to osteoporosis and avascular necrosis of the
humeral head [5]. According to Hertel et al. [6] frac-
tures of the proximal humerus involving the anatomical
neck are mostly at risk for developing ischemia. There-
fore, primary hemiartroplasty may be preferable over
locking plates for these specific fracture types in the
elderly.
Primary hemiarthroplasty and non-operative treatment
of comminuted proximal humeral fractures have been
described in a number of studies with varying functional
results [7-15]. Up till now, only one RCT comparing
HA with non-operative treatment has been published;
less pain and better overall function was reported for
the HA group (N = 32 patients) [13]. However, due to
methodological limitations (e.g., indistinct inclusion cri-
teria and differences in age at baseline) the outcome of
this RCT may not be generalizable. A properly designed
RCT is needed in order to gain insight into the best
treatment for those comminuted proximal humeral frac-
tures that are mostly at risk for avascular necrosis.
Study objectives
The primary aim of this study is to compare the Con-
stant score, reflecting functional outcome and pain, after
primary hemiarthroplasty (HA) versus non-operative
treatment in patients over 65 years of age who sustained
a comminuted fracture of the proximal humerus.
Secondary aims are to determine the effect of primary
HA versus non-operative treatment on the degree of
disabilities of the arm, shoulder and hand (DASH
score), level of pain (VAS), the rate of secondary inter-
ventions, complications and mortality, the radiographic
healing, and the health-related quality of life (Short-
Form 36, SF-36, and EuroQol-5D, EQ-5D) in these
patients. Finally, upon calculation of the costs for both
the HA and the non-operative groups, the cost-effective-
ness of these treatments will be determined and
compared.
Based upon limited literature data available, our main
study hypothesis is that HA will result in higher
Constant scores (reflecting better functional outcome
with less pain) at 1 year compared with non-operative
treatment of comminuted proximal humeral fractures in
the elderly Despite higher initial costs, it is expected
that HA will be more cost-effective than conservative
treatment.
Methods/Design
Study design
The ProCon trial will follow a multicenter randomized
controlled trial design. Eight centers in the Netherlands
and one in Belgium will participate. The study started
June 15, 2009. The trial has been designed in accor-
dance with de Declaration of Helsinki (59th World
Medical Association General Assembly, Seoul, October
2008) [16] and in accordance with the Medical Research
Involving Human Subjects Act. It will follow the CON-
SORT (CONsolidation of Standards of Reporting Trials)
guidelines [17,18].
Recruitment and consent
Eligible persons presenting to the Emergency Depart-
ment (ED) with a comminuted proximal humeral frac-
ture will be informed about the trial at the ED. They will
receive information and a consent form from the attend-
ing physician, the clinical investigator or a research assis-
tant. After providing written informed consent, eligible
patients will be randomized to two treatment strategies.
Variable block randomization will be accomplished via a
trial website. Allocation will be at random. Follow-up will
take place over a period of two years.
Study population
All persons aged 65+ who present at the Emergency
Department with a comminuted fracture of the proximal
humerus are eligible for inclusion. Presence of a proxi-
mal humeral fracture can be confirmed on X-ray, how-
ever fracture classification requires 3-dimensional
Computed Tomography (CT) reconstructions [6,19].
Patients meeting the following inclusion criteria are
eligible for enrolment:
1. Adult men or women aged 65 years and older (with
no upper age limit)
2. Fracture of the humeral head
3. Selected three-part (Hertel classification type 9, 10,
11), selected four-part (Hertel type 12), anatomical neck
(Hertel type 2), or split-head fractures of the humeral
head in the judgement of the attending surgeon. All
fractures should be classified according to the binary
description system, based on 3D CT reconstructions
(Figure 1 and 2)
4. Operative treatment within 21 days (if randomized
for HA)
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6. Assurance that the surgeon who will perform HA
has attended the pre-trial HA course (Erasmus MC
Skills lab)
If any of the following criteria applies, patients will be
excluded:
1. Polytrauma patients
2. Patients with an additional traumatic injury of the
affected arm
3. Patients with a pathological, recurrent or open
humerus fracture
4. Patients with an impaired shoulder function (i.e.,
stiff or painful shoulder, neurologic disorder of the
upper limb, or diagnosed rotator cuff impairment) prior
to the injury
5. Retained hardware around the affected humerus
6. Patients with a disorder of bone metabolism other
than osteoporosis (e.g., Paget’s disease, renal osteody-
strophy, osteomalacia)
7. Moderate or severe cognitively impaired patients
(i.e., Mini-Mental Status Examination (MMSE) Six Item
Screener with 3 or more errors)
8. Likely problems, in the judgment of the investiga-
tors, with maintaining follow-up (e.g., patients with no
fixed address will be excluded)
9. Insufficient comprehension of the Dutch language to
understand a rehabilitation program and other treatment
information in the judgment of the attending physician
The Six Item Screener for dementia (exclusion criter-
ion 7) is a brief and reliable instrument for identifying
subjects with cognitive impairment. The patient is asked
to remember three words (e.g., apple, table, penny), then
to say the day of the week, month, year, and finally to
recall the three words without prompts. Using a cut-off
of 3 or more errors, the sensitivity and specificity of the
Six Item Screener for diagnozing dementia was 88.7 and
88.0, respectively [20].
Exclusion of a patient because of enrolment in another
ongoing drug or surgical intervention trial will be left to
the discretion of the attending surgeon, on a case-by-
case basis.
Interventions
Patients will be randomized to either hemiarthroplasty
or conservative treatment.
Hemiarthroplasty (Figure 3A) will be performed using
the Affinis® Fracture shoulder endoprosthesis (Mathys
AG Bettlach). No other prosthesis types will be used in
order to increase homogeneity of data. Critical steps of
t h es u r g i c a lp r o c e d u r ew i l lb es t a n d a r d i z e d .S t a n d a r -
dized items will include the positioning of the patient
(i.e., beach-chair position, with the scapula supported)
and anesthesia (i.e., general or interscalene nerve block),
surgical approach (a modified lateral deltoid split
approach), exposure, shaft preparation, stem placement
and cementing, and fixation of the tubercles with a
cable wire [21]. After surgery, patients are allowed to
u s eas l i n gf o rt w od a y st oo n ew e e k .P a t i e n t sw i l l
Figure 1 Binary (LEGO) description system of the Hertel
classification of proximal humerus fractures. The 12 basic
fracture patterns result after combining the 5 basic fracture planes.
Basic fracture planes lie between the greater tuberosity and the
head, the greater tuberosity and the shaft, the lesser tuberosity and
the head, the lesser tuberosity and the shaft, and the lesser
tuberosity and the greater tuberosity. There are 6 possible fractures
dividing the humerus into two fragments, 5 possible fractures
dividing the humerus into three fragments, and a single fracture
dividing the humerus into four fragments Categories eligible for
enrolment into the current trial are indicated in red boxes.
Reprinted from J Shoulder Elbow Surg, 13, Hertel R, Hempfing
A, Stiehler M, Leunig M: Predictors of humeral head ischemia
after intracapsular fracture of the proximal humerus, pp 427-
433, with permission from Elsevier.
Figure 2 Head-split components. Classic head-split geometry (left)
and special head-split geometry where both fragments remain
perfused (right). Categories eligible for enrolment into the current
trial are indicated in red boxes. Reprinted from J Shoulder Elbow
Surg, 13, Hertel R, Hempfing A, Stiehler M, Leunig M:
Predictors of humeral head ischemia after intracapsular
fracture of the proximal humerus, pp 427-433, with permission
from Elsevier.
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col, developed by an experienced physical therapist
(Dept. of Rehabilitation and Physical Therapy, Erasmus
MC, Rotterdam, The Netherlands). Anteflexion and ele-
vation exercises may be started immediately if tolerated.
Rotation exercises against resistance are not allowed
during the first six weeks after surgery. Physical therapy
sessions will be held at regular intervals, preferably two
times a week during 12 weeks. The exact frequency and
duration of physical therapy will largely depend upon
the extent of functional recovery. This will be left at the
discretion of the therapist.
In order to ensure similar peri-operative regimens,
participating centers will standardize the following key
aspects of pre-and post-operative care. Pre-operatively,
patients will receive antibiotic prophylaxis (single dose)
and thromboprophylaxis, and their condition prior to
surgery will be optimized if necessary. Post-operatively,
patients will receive thomboprophylaxis during hospital
stay (e.g., unfractionated heparin, Low Molecular
Weight Heparin (LMWH), or equivalent). Surgical delay
and physical therapy and rehabilitation programs be
recorded but not standardized.
Conservative treatment (Figure 3B) is defined by treat-
ment with a collar and cuff for three weeks. After one
week circumduction exercises will start under supervision
of a physical therapist. At three weeks after trauma, full
range of motion excercises will be initiated if tolerated.
Physical therapy sessions will be held at regular intervals,
preferably two times a week during 12 weeks. The exact
frequency and duration of physical therapy will largely
depend upon the extent of functional recovery. This will
be left at the discretion of the therapist. Details of the ther-
apy program will be recorded.
Pre-trial hemiarthroplasty course
In order to ensure that all participating surgeons per-
form the surgical procedure in a similar manner, they
will attend a one-day technique-oriented training prior
to the commencement of the trial. The training will be
held at the Surgical Skills Lab (Erasmus MC, Rotterdam,
the Netherlands) and will be given by experienced sur-
geons (DDH, NWLS, SN). The surgical procedure will
be practiced on human cadavers, with main focus on
the critical aspects of the surgery including surgical
approaches and implant-related insertion guidelines for
the implant used. A refresher course will be planned
after 6 months in order to ensure that sufficient knowl-
edge is maintained. After each operation, surgeons will
have to complete a surgical report form, in which space
will be provided to report deviations, if any. Two experts
(DDH and NWLS) will judge if surgery has been
Figure 3 Examples of proximal humerus fracture, managed by endoprosthesis (A) or conservative treatment (B).
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vide feedback to the surgeon.
Outcome measures
The primary outcome measure will be the Constant
score. This scoring system consists of four variables,
reflecting both function and pain of the shoulder joint
[22]. The subjective variables are pain (15 points), activ-
ities of daily living (ADL; i.e., sleep, work, recreation/
sport; 10 points), and arm positioning (10 points), which
give a total of 35 points. The objective variables are
range of motion (ROM; 40 points) and strength (25
points), which give a total of 65 points. ROM includes
forward flexion (10 points), lateral elevation (10 points),
external rotation related to the head (10 points) and
internal rotation related to the spine column (10 points).
Forward flexion and lateral elevation are measured using
a goniometer. Strength of abduction will be measured
using a calibrated spring balance. The right and left
shoulders will be assessed separately.
Secondary outcome measures are:
- Disabilities of the Arm, Shoulder and Hand (DASH)
score
- Visual Analogue Scale (VAS) for pain
- Rates of secondary interventions
- Radiographic healing
- Mortality rate
- Complication rates
- Health-related quality of life: Short Form-36 (SF-36)
- Health Utility: EuroQol-5D (EQ-5D)
- Healthcare consumption (for cost calculations)
- Cost-effectiveness
The Disabilities of the Arm, Shoulder and Hand
(DASH) Outcome Measure is a validated 30-item, self-
report questionnaire designed to help describe the dis-
ability experienced by people with upper-limb disorders
and also to monitor changes in symptoms and function
over time [23-25]. The DASH outcome measure is
scored in two components: the disability/symptom sec-
tion (30 items, scored 1-5) and the optional high perfor-
mance Sport/Music module (4 items, scored 1-5). The
DASH disability/symptom score is a summation of the
responses to 30 questions on a scale of 1 to 5. Scores
may range from 0 points (no disability) to 100 points
(severe disability). The questions test the degree of diffi-
culty in performing a variety of physical activities
because of arm, shoulder, or hand problems (21 items).
They also investigate the severity of pain, activity-related
pain, tingling, weakness, and stiffness (5 items), as well
as the effect of the upper limb problem on social activ-
ities, work, sleep, and self-image (4 items).
Pain level will be determined using a 10-point Visual
Analog Scale, in which 0 implies no pain and 10 implies
the worst imaginable pain.
Secondary interventions within one year of initial
treatment to promote fracture healing, relieve pain, treat
infection, or improve function include the following:
1. (Reversed) Arthroplasty placement (conservative
group only)
2. Plate fixation (conservative group only)
3. Incision and drainage for s u p e r f i c i a ls u r g i c a ls i t e
infection (HA group only)
4. Incision and drainage for deep surgical site infection
(HA group only)
5. Revision to Affinis® Reversed prosthesis (HA group
only)
6. Implant exchange (HA group only)
7. Implant removal (HA group only)
Radiographic healing will be determined using CT
scanning at one year. Location and consolidation of the
tubercles will be scored in duplicate by two experienced
surgeons (DDH and NWLS). In case of differences
between them, they will discuss the images until they
reach an agreement.
Complications: complication rates in the HA group
may include infection, neurovascular injury, malposi-
tioning of the prosthesis, asceptic loosening of the pros-
thesis, dislocation of the tubercles. Complication rates in
the control group may include malunion, nonunion, sec-
ondary dislocation, and symptomatic avascular necrosis
of the humeral head.
The Short-Form 36 is a validated multi-purpose,
short-form health survey with 36 questions, representing
eight health domains that are combined into a physical
and a mental component scale [26]. The Physical Com-
ponent Scale (PCS) combines the health domains physi-
cal functioning (PF; 10 items), role limitations due to
physical health (RP; 4 items), bodily pain (BP; 2 items),
and general health perceptions (GH; 5 items). The Men-
tal Component Scale (MCS) combines the health
domains vitality, energy, or fatigue (VT; 4 items), social
functioning (SF; 2 items), role limitations due to emo-
tional problems (RE; 3 items), and general mental health
(MH; 5 items). Scores ranging from 0 to 100 points are
derived for each domain, with lower scores indicating
poorer function. These scores will be converted to a
norm-based score and compared with the norms for the
general population of the United States (1998), in which
each scale was scored to have the same average (50
points) and the same standard deviation (10 points).
The EuroQol (EQ-5D) is a validated and extensively
used general health questionnaire to measure quality of
life [27,28]. It is recommended for the assessment of
QoL in trauma patients, especially for economic assess-
ments [29,30]. EQ-5D has been developed by the Euro-
QoL Group in order to provide a simple, generic
measure of health for clinical and economic appraisal
[31]. EQ-5D consists of the EQ-5D descriptive system
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descriptive system comprises five dimensions: mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression. Each dimension is marked as either no pro-
blems, some problems, or severe problems, which
results in a 1-digit number expressing the level selected
for that dimension. The digits for five dimensions are
combined in a 5-digit number describing the respon-
dent’s health state. The EQ VAS records the respon-
dent’s self-rated health on a vertical, visual analog scale.
Scores ranging from 0 (’Worst imaginable health state’)
to 10 (’Best imaginable health state’) can be used as a
quantitative measure of health outcome as judged by
the individual respondents.
Cost measurement will be in accordance with Dutch
guidelines for economic evaluations. Healthcare consump-
tion data will be collected using a custom-made question-
naire. Health care costs will include costs of general
practice care, medical specialist care, physical therapy, hos-
pitalization, medication, home care, and other costs
directly associated with diagnosis, treatment and rehabili-
tation. Where possible standard cost prices will be used as
published by Oostenbrink will be used [32]. In accordance
with guidelines for differential discounting, effects will be
discounted at a rate of 1.5% and costs at 4% per year [33].
Results will be presented with 95% confidence intervals.
The incremental cost-effectiveness ratio of HA versus
conservative treatment will be expressed in a cost-utility
ratio, i.e., in terms of cost per Quality-Adjusted Life
Years (QALY). Cost-utility ratios will be calculated by
dividing the difference in mean costs of the two inter-
ventions by the difference in their mean effects. Policy
makers and healthcare economists have proposed that
costs varying from € 25,000 up to € 75,000 (US$ 31,600
- US$ 94,700) per QALY may be considered as accepta-
ble [34,35].
In addition to the outcome variables mentioned above,
the following data will be collected:
a) Intrinsic variables (baseline data): dominant side,
age, gender, American Society of Anesthesiologists
(ASA) grade, alcohol and tobacco consumption, comor-
bidity including osteoporosis, household composition,
and medication use
b) Injury related variables: affected side, mechanism of
injury, fracture classification (Hertel)
c) Intervention-related variables: surgical delay (i.e.,
time between fracture and surgery; HA-group only),
time between injury and start of physical therapy, days
of collar and cuff use, and total number of physical ther-
apy sessions
Follow up of patients
Patients will be followed for two years. In addition, at
the 2-year follow-up (FU) visit, any secondary interven-
tion planned will be recorded. A schedule of events is
shown in Figure 4.
Clinical assessments will occur at the time of admis-
sion to the hospital (baseline), one week (3-10 days win-
dow), three weeks (11-28 days window), six weeks
(4-8 weeks window), three months weeks (11-15 weeks
window), six months (5-7 months window), 12 months
(11-13 months window), and 24 months (24-26 months
window) after surgery (HA group) or after start of
conservative treatment (conservative group).
Figure 4 Schedule of follow-up measurements.
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injury-related variables will be collected. At the three,
six, 12, and 24 months FU visit, an independent
researcher will determine the Constant score. In order
to prevent bias the Constant score will be determined
by an independent assessor. At each clinic FU visit, the
researcher will ascertain patient status (i.e., secondary
interventions, adverse events/complications, deaths), and
will verify information within medical records. At each
visit, patients will be asked to complete the question-
naires relating to disability (DASH score), and VAS for
pain. From six weeks onwards, SF-36, EQ-5D, and
health care consumption questionnaires will also be
completed. A postal version of the latter questionnaire
will be sent at 18 months in order to minimize recall
bias.
As part of standard of care, X-rays of the shoulder will
be made at the time of admission to hospital (baseline),
at one, three and six weeks, and three and 12 months
after surgery (HA group) or start of conservative treat-
ment. CT scans that will be conducted pre-treatment,
which are required for correct classification of the frac-
ture, are also part of standard of care. As part of this
trial, one additional CT-scan will be made at 12 months
FU in order to determine consolidation (i.e. vanishing
tubercles).
Sample size calculation
Calculation of the required sample size is based on the
assumption that the mean Constant score will be 47 in
the conservatively treated patients and 56 in the HA
group, assuming a SD of 12 for each group [10,14].
A two-sided test with an alpha level of 0.05 and a beta
level of 0.2 requires 30 patients in every group. Antici-
pating a mortality rate of 10% in the first year due to a
natural death rate in elderly patients [36], and a conser-
vative dropout rate of 20% loss-to-follow up (based
upon experience in previous trials), projects to a
required sample size of 40 per group.
Statistical analysis
The research data will be reported following the CON-
solidated Standards of Reporting Trial (CONSORT).
Data will be analyzed using the Statistical Package for
the Social Sciences (SPSS) version 16.0 or higher (SPSS,
Chicago, Ill., USA). Normality of continuous data will be
tested with the Shapiro Wilk test, and homogeneity of
variances will be tested using the Levene’s test. Protocol
violations will be recorded; data will be analyzed with
and without patients with protocol violation.
Differences in baseline characteristics (i.e., intrinsic
and injury-related variables) between both intervention
groups will be assessed using the Student’s T-test (para-
metric numeric data), Mann-Whitney U-test (non-
parametric numeric data) or Chi-square test (categorical
data). Data will be presented as mean ± SD (parametric
data) or medians and percentiles (non-parametric data).
Univariate analysis will be performed to test the differ-
ence in primary and secondary outcome measures
between the intervention groups using the Student’s
T-test (parametric data), Mann Whitney U-test (non-
parametric data) or Chi-square analysis (categorical data).
Multinomial logistic regression analysis will be
performed to model the relation between different
covariates and the Constant score. Intrinsic and
fracture-related variables that display a p-value < 0.5 in
univariate analyses will be added as covariate. Similar
models will be made to model the relation between
covariates and the other outcome measures.
A p-value < 0.05 (2-sided tests) will be taken as
threshold of statistical significance.
Ethical considerations
The Medical Ethics Committee Erasmus MC acts as
central ethics committee for this trial (reference number
MEC-2009-178; NL26320.078.09). Approval has been
obtained from the local Medical Ethics Committees in
all participating centers. An information letter notifying
the patients’ participation will be sent to their general
practitioners, unless a patient does not agree with this.
The Medical Ethics Committee Erasmus MC has given
dispensation from the statutory obligation to provide
insurance for subjects participating in medical research
(Medical Research (Human Subjects) Compulsory Insur-
ance Decree of 23 June 2003), because participation in
this study is without risks.
Discussion
The optimal treatment of three-or four part fractures
and split head humeral fractures, with a high risk of
developing head necrosis, is an unresolved problem in
the elderly. The treatment of these fractures consists of
conservative and operative strategies.
In general, hemiarthroplasty of the shoulder is indi-
cated for the more complex fracture types; shoulder
arthroplasty remains a valuable solution for the treatment
of the non-reconstructable proximal humeral fractures in
the elderly patients. A systematic literature review of 33
studies encompassing 1096 patients with three-or four-
part proximal humeral fractures that used the Constant
score as outcome measure, however, failed to proof
superiority of HA over conservative treatment [37].
The results of this study will help clarify the question
if primary HA is superior to non-operative treatment in
selected proximal humeral fractures in the elderly.
Higher Constant scores (reflecting better functional out-
come with less pain) at one year are expected for the
HA group. Better function and less pain may result in a
Den Hartog et al. BMC Musculoskeletal Disorders 2010, 11:97
http://www.biomedcentral.com/1471-2474/11/97
Page 7 of 9better quality of life of patients. This may lead to a
higher level of independency, and less health care con-
sumption needs. Although costs for initial treatment will
be higher in the HA-group (due to surgery) than in the
non-operative group, it is expected that HA will be a
cost-effective approach.
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